At Verastem Oncology, Inc. (NASDAQ: VSTM), we’re working to develop a portfolio of novel small-molecule drugs that inhibit critical RAS signaling pathways that promote cancer cell survival and tumor growth. We’re pushing beyond what’s known about cancer treatment and working to deliver novel treatment approaches that address areas of high unmet need in RAS pathway-driven cancers.
Our focus is on bringing new and better treatment options to patients who are battling these cancers—such as low-grade serous ovarian cancer and KRAS mutant non-small cell lung cancer. These types of cancer are extremely difficult to treat, and there are limited effective therapeutic options available. That means many patients run out of options and time. We’re committed to changing that.
Verastem is a member of NASDAQ Biotechnology Index. For additional information, please contact Nate LiaBraaten at Argot Partners by phone at (212) 600-1902, or by email at email@example.com.
For an in-depth look at our research program, financial data, and corporate proxy statements, please access our investor kit.
Find our SEC filings here.
Focused on Areas of High Unmet Need
With the vision of VS-6766 as a backbone of therapy for treatment of RAS pathway-dependent tumors, we are developing indication-specific combinations with VS-6766, a unique RAF/MEK clamp, including combination with defactinib, a selective FAK inhibitor, to expand the options available to patients with these common and difficult-to-treat mutations.
Blocking the RAS Signaling Pathway
Based on a thorough understanding of the signaling pathways that cancer employs to maintain its growth and circumvent RAS pathway-targeting drugs, our customized combinations with VS-6766 are designed to deliver deeper and more durable responses for cancer patients who have limited effective options.